Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Wesche

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid TumorsMary Ellen Molloy, Richard J Austin, Bryan D Lemon, et al.
Molecular Cancer Therapeutics|November 18, 2020
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid TumorsRichard J Austin, Bryan D Lemon, Wade H Aaron, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Molecular Cancer Therapeutics|April 26, 2024
HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid TumorsMary E Molloy, Wade H Aaron, Manasi Barath, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part II: description of a potent and pharmacologically active series of analogsTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hitTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid TumorsMary Ellen Molloy, Richard J Austin, Bryan D Lemon, et al.
Molecular Cancer Therapeutics|November 18, 2020
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid TumorsRichard J Austin, Bryan D Lemon, Wade H Aaron, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Molecular Cancer Therapeutics|April 26, 2024
HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid TumorsMary E Molloy, Wade H Aaron, Manasi Barath, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part II: description of a potent and pharmacologically active series of analogsTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hitTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.
Pageof 3